The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: The effects of risedronate on BMD and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer - First results

被引：0
|
作者：
Van Poznak, C.
Hannon, R. A.
Clack, G.
Campone, M.
Mackeys, J. R.
Apffelstaedt, J.
Eastell, R.
机构：
[1] Univ Michigan, Ctr Comprehens Canc, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Sheffield, Acad Unit Bone Metabol, Sheffield, S Yorkshire, England
[3] AstraZeneca, Macclesfield, Cheshire, England
[4] Site Hosp, Ctr Rene Gauducheau, Nord de Nantes, France
[5] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
[6] Univ Stellenbosch, Dept Surg, Tygerberg, South Africa
来源：
BONE | 2007年 / 40卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S159 / S160
页数：2
相关论文
共 50 条
  • [41] The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer
    Lim, Elgene
    Carson, Emma
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 194 - 195
  • [42] The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer
    Carson, E.
    Segara, D.
    Parker, A.
    O'Toole, S.
    Coates, A.
    Mann, B.
    Lindeman, G.
    Tilley, W.
    Lim, E.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [43] Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study
    Ruiz-Borrego, Manuel
    Guerrero-Zotano, Angel
    Bermejo, Begona
    Ramos, Manuel
    Cruz, Josefina
    Manuel Baena-Canada, Jose
    Cirauqui, Beatriz
    Rodriguez-Lescure, Alvaro
    Alba, Emilio
    Martinez-Janez, Noelia
    Munoz, Montserrat
    Antolin, Silvia
    Alvarez, Isabel
    Del Barco, Sonia
    Sevillano, Elena
    Ignacio Chacon, Jose
    Anton, Antonio
    Jose Escudero, Maria
    Ruiz, Victoria
    Carrasco, Eva
    Martin, Miguel
    Segui, M. A.
    Ayala, F.
    de la Haba, J.
    Martinez, P.
    Gonzalez, S.
    Lahuerta, A.
    Toral, J. C.
    Martinez de Duenas, E.
    Florian, J.
    Godes, M. J.
    Llorca, C.
    Blancas, I.
    Jara, C.
    Morales, S.
    Arcusa, A.
    Martinez, A.
    Vicente, E.
    de Juan, A.
    Rodriguez, M.
    Garcia, M.
    Garcia, P.
    Bayo, J. L.
    Caranana, V.
    Casinello, J.
    Jolis, L.
    Gil, M.
    Canabate, C.
    Oltra, A.
    Ramirez, J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (01) : 115 - 125
  • [44] Phase II chemoprevention trial: Anastrozole in DCIS and early invasive hormone-receptor (HR) positive breast cancer in postmenopausal women.
    Huynh, Richard
    Mehta, Rita S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] The effect of using adjuvant aromatase inhibitors on cognitive functions in postmenopausal women with hormone receptor-positive breast cancer
    Ilhan, Rukiye Guler
    Ilhan, Yusuf
    Goksu, Sema Sezgin
    Tatli, Ali Murat
    Coskun, Hasan Senol
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) : S368 - S372
  • [46] The effects of toremifene (TOR) and anastrozole (ANA) on serum lipids and bone metabolism in postmenopausal patients with estrogen receptor (ER) positive breast cancer; multi-center study
    Mitsuyama, S.
    Yanagida, Y.
    Doihara, H.
    Komaki, K.
    Kusama, M.
    Ikeda, T.
    Kimura, M.
    Sano, M.
    Miyauchi, K.
    Anan, K.
    [J]. BREAST, 2007, 16 : S45 - S45
  • [47] Winpro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer
    Lau, Brandon
    Segara, Davendra
    Ong, Andrew
    Bingham, Janne
    Kiely, Belinda
    Carson, Emma-Kate
    Chen, Julia
    Mak, Cindy
    Warrier, Sanjay
    Hui, Mun
    Middleton, Kate
    Parker, Andrew
    Mann, Bruce
    Lindeman, Geoffrey
    Tilley, Wayne
    Lim, Elgene
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [48] Comparison of the cost-effectiveness of letrozole or anastrozole versus tamoxifen as adjuvant therapies for early breast cancer in hormone receptor positive (HR+) postmenopausal women: The UK perspective
    Karnon, Jonathan
    Delea, Thomas
    Papo, Natalie L.
    Barghout, Victoria
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 107 - 107
  • [49] Cost-effectiveness analysis of anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC): a UK perspective
    Simons, R
    Bassi, R
    Jones, D
    Barrett-Lee, P
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68
  • [50] A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Cristofanilli, M.
    Valero, V.
    Mangalik, A.
    Rabinowitz, I.
    Arena, F. P.
    Kroener, J. F.
    Curcio, E.
    Watkins, C.
    Magill, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345